The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.

Inclusion Criteria: 1. primary lung squamous carcinoma confirmed by cytology and histology, excluding sputum examination. 2. phase IIIB /IV based on IASLC 2009 TNM criteria. 3. at least one measurable tumor based on RECIST 1.1 ( longest diameter: ≥20 mm by CT scan or 10 mm by spiral CT ) 4. male or female, age≥18 or ≤75 years old 5. ECOG PS: 0 or 1 6. estimated time of survival: ≥ 3 months 7. suitable hematologic function: ANC≥2×109/L, PLC≥100×109/L and Hb≥9 g/dL 8. suitable liver function: Total bilirubin≤normal ULN, AST and ALT≤2.5×normal ULN, ALP≤5×normal ULN. 9. suitable renal function: Cr≤normal ULN,or Ccr≥60 ml/min 10. EKG normal 11. without no healing wound 12. no history of anti-cancer therapy, or adjuvant/neo-adjuvant chemotherapy for non-metastatic tumor finished for more than 6 months before enrolment. 13. for the female subject with productive ability, urine pregnancy test must be done and is negative within 7 days before enrolment. 14. no history of serious allergic to biologic agents, especially E.Coli products 15. the authorized ICF must be signed Exclusion Criteria: 1. Woman in pregnancy and breast-feeding, or having productive ability without contraception. 2. Having the serious acute infection uncontrolled or purulent/chronic infection with unhealed wound. 3. Having the serious heart disease, including congestive heart failure, uncontrolled high-risk arrhythmia, unstable angina, myocardial infarction, valvular disease, and refractory hypertension. 4. Having uncontrolled nervous or mental disease with low compliance and reluctance to description of response; uncontrolled primary brain tumor or other metastatic brain cancer with obvious intracranial hypertension or mental symptoms. 5. Having the tendency of bleeding, such as FIB\<2G/L 6. Being receiving adjuvant chemotherapy. 7. On other conditions investigator considers, the subject is not fitful to participate the trial.